ArticleArthritis research2002
Autoantibodies directed to novel components of the PM/Scl complex, the human exosome.
Article in Arthritis research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 87 citations in OpenAlex.
- [Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Polyadenylated versions of small non-coding RNAs inMicrobial cell (Graz, Austria) · 2024Article
- Negative ANA-IIF in SLE patients: what is beyond?Clinical rheumatology · 2023Article
- Anti-PM/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement.Internal medicine (Tokyo, Japan) · 2021Article
- Molecular characteristics and functional differences of anti-PM/Scl autoantibodies and two other distinct and unique supramolecular structures known as "EXOSOMES".Autoimmunity reviews · 2020Review
- From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers.Methods (San Diego, Calif.) · 2020Review
- Association between antinuclear antibodies (ANA) patterns and extractable nuclear antigens (ENA) in HEp-2 cells in patients with autoimmune diseases in Riyadh, Saudi Arabia.Intractable & rare diseases research · 2020Article
- Antinuclear Antibodies in Systemic Sclerosis: an Update.Clinical reviews in allergy & immunology · 2020Review
- Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives.Journal of scleroderma and related disorders · 2018Review
- The clinical phenotype of patients positive for antibodies to myositis and myositis-related disorders.Clinical rheumatology · 2018Article
- The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis.Cellular & molecular immunology · 2017Article
- High-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis.Genome medicine · 2016Article
- Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis.Arthritis research & therapy · 2016Article
- Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.Arthritis research & therapy · 2015Article
- Article
- Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis.Arthritis research & therapy · 2012Article
- Activities of human RRP6 and structure of the human RRP6 catalytic domain.RNA (New York, N.Y.) · 2011Article
- The exozyme model: a continuum of functionally distinct complexes.RNA (New York, N.Y.) · 2011Review
- Structural and biochemical characterization of CRN-5 and Rrp46: an exosome component participating in apoptotic DNA degradation.RNA (New York, N.Y.) · 2010Article
- Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.Arthritis research & therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The autoantigenic polymyositis/scleroderma (PM/Scl) complex was recently shown to be the human homologue of the yeast exosome, which is an RNA-processing complex. Our aim was to assess whether, in addition to targeting the known autoantigens PM/Scl-100 and PM/Scl-75, autoantibodies also target recently identified components of the PM/Scl complex. The prevalence of autoantibodies directed to six novel human exosome components (hRrp4p, hRrp40p, hRrp41p, hRrp42p, hRrp46p, hCsl4p) was determined in sera from patients with idiopathic inflammatory myopathy (n = 48), scleroderma (n = 11), or the PM/Scl overlap syndrome (n = 10). The sera were analyzed by enzyme-linked immunosorbent assays and western blotting using the affinity-purified recombinant proteins. Our results show that each human exosome component is recognized by autoantibodies. The hRrp4p and hRrp42p components were most frequently targeted. The presence of autoantibodies directed to the novel components of the human exosome was correlated with the presence of the anti-PM/Scl-100 autoantibody in the sera of patients with idiopathic inflammatory myopathy (IIM), as was previously found for the anti-PM/Scl-75 autoantibody. Other clear associations between autoantibody activities were not found. These results further support the conception that the autoimmune response may initially be directed to PM/Scl-100, whereas intermolecular epitope spreading may have caused the autoantibody response directed to the associated components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.